Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

A Harvard team reverses dementia in mice with a metal supplement, after showing that its deficiency drives the disease ...

Lithium could help treat cases of Alzheimer’s disease, a Harvard study suggests. People with the neurodegenerative condition ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, ...

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...